#None #Scinai Immunotherapeutics #biopharmaceuticals #CDMO Services

Scinai Immunotherapeutics Reports Financial Results

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has released its financial report for the first half of 2025, showcasing substantial growth in revenues and improvements in its financial standing. The company, which specializes in developing innovative biological therapies, recorded revenues of $773,000 for the six months ending June 30, 2025. This marks a significant rise from the $284,000 reported for the same period in the previous year, largely driven by enhanced performance in its Contract Development and Manufacturing Organization (CDMO) services.

Financial Highlights

The company's revenue growth is indicative of its successful CDMO offerings, which have started to gain traction. For the first half of 2025, the expenses associated with research and development (R&D) were reported at $1,237,000, a sharp decline from $2,788,000 during the same time in 2024. This reduction is primarily attributed to decreased wages and facility costs allocated to R&D activities.

However, marketing, general, and administrative expenses saw an uptick to $1,256,000, compared to $1,003,000 in 2024, mainly due to new share-based payments and an insurance reimbursement recorded in the previous year. Overall, Scinai's net loss decreased to $4,134,000, down from $4,481,000, reflecting improvements in revenue levels coupled with trimmed R&D costs.

As of June 30, 2025, the company’s cash and cash equivalents stood at $989,000. Following this period, Scinai successfully raised an additional $4.2 million through its Standby Equity Purchase Agreement with Yorkville Advisors, fortifying its cash position and enhancing its ability to fund future projects.

Business Update on CDMO Services

Scinai's CDMO business unit, Scinai Bioservices, exhibits promising growth with a reported revenue contribution of $421,000 from its U.S. subsidiary in the first half of 2025. By August 31, 2025, the total CDMO service orders for the year reached $1 million, net of raw materials and disposables, resulting in invoiced revenues of approximately $850,000.

Advancements in Research and Development

On the R&D front, Scinai is making strides with its anti-IL-17 NanoAb program, developing two product profiles targeting psoriasis treatments. The company aims to embark on Phase 1/2a clinical trials and is seeking up to €15 million in grant funding under the EU STEP program, anticipating a decision in the first quarter of 2026.

In 2025, Scinai has filed patents for four additional NanoAbs from its collaboration with the Max Planck Society and University Medical Center Göttingen, while also planning to apply for a European Funds for a Modern Economy (FENG) grant to fund novel multi-specific antibody development for TH2-related diseases.

Furthermore, in March 2025, Scinai signed an option agreement to acquire PinCell srl, an Italian biotech firm focusing on potential treatments for severe skin conditions, with related grant applications currently under review.

Conclusion

Scinai Immunotherapeutics is clearly on a growth trajectory as it continues to expand its CDMO business and enhance its R&D portfolio, reflecting its commitment to addressing significant medical needs in inflammation and immunology. As the company pushes forward with clinical trials and product developments, it sets a promising stage for future advancements in the biopharmaceutical sector.